Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition
ReutersApr 18, 2025 3:26 PM
April 18 (Reuters) - The U.S. Food and Drug Administration approved the extended use of Sanofi SASY.PA and Regeneron's REGN.O blockbuster drug Dupixent for patients with a type of skin condition, the two companies said on Friday.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
VIX Off Its Highs — Is a U.S. Market Rebound Taking Shape?
TradingKey - The Cboe Volatility Index (VIX), widely regarded as Wall Street’s "fear gauge," has dropped sharply after briefly surging above 50 last week. It has since pulled back to the 30 range.TradingKey
Fri, Apr 18
TSMC's Q1 2025 Earning: Technological leadership and AI demand drive continued growth in performance
For investors, TSMC's current valuation has not yet fully reflected its growth potential in the AI chip market. It is recommended to pay attention to its progress in 2nm process mass production and CoWoS capacity expansion.TradingKey
Thu, Apr 17
[Reuters Breakingviews] Trump kicks all of Asia into the China tariff boat
HONG KONG, April 3 (Reuters Breakingviews) - Donald Trump’s second trade war is a battle of one against all. Reciprocal tariffs announced on Wednesday by the White House hit China with a hike of 34 percentage points, taking the fresh levies on exports from the People’s Republic up 5...Reuters
Thu, Apr 3
US Stock Market’s 2025 Outlook: Navigating the Shifting Landscape
TradingKey - Anyone who has invested in US stocks in 2024 will be happy. The US stock market has delivered an absolutely blockbuster performance so far this year, with the S&P 500 Index soaring 26.9% year-to-date (as of December 16), reaching record highs.TradingKey
Mon, Dec 30
